Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
The final 5-year analysis of the HOPE-B trial confirms that etranacogene dezaparvovec provides stable, long-term factor IX expression and clinical protection for patients with hemophilia B, effectively eliminating the need for routine proph
The VAYHIT2 Phase 3 trial demonstrates that adding the BAFF-R monoclonal antibody ianalumab to eltrombopag significantly extends treatment-free intervals and improves stable response rates in patients with relapsed or refractory immune thro
The Phase 3 VAYHIT2 trial reveals that combining ianalumab with eltrombopag significantly extends freedom from treatment failure and increases stable response rates in patients with second-line immune thrombocytopenia, potentially offering
Cochrane review shows uncertain effects of riboflavin on blood pressure, highlighting a need for larger and better-quality trials.
ASPREE randomized ~19,000 older adults to low‑dose aspirin or placebo. Over ~4.7 years, aspirin did not improve disability‑free survival or reduce cardiovascular events, increased major bleeding, and showed a surprising rise in cancer‑relat
A large target‑trial emulation of US claims data found continued oral anticoagulation after ≥90 days for unprovoked VTE markedly reduced recurrent VTE and mortality, increased major bleeding, but produced an overall net clinical benefit tha
A large clinical trial compared Mobile Integrated Health with standard care coordination for heart failure patients after hospital discharge, finding no significant overall benefits but highlighting potential age-related effects.
A multicenter phase 2 randomized trial found no differential benefit of adaptive computerized cognitive training, structured cognitive rehabilitation, or transcranial direct current stimulation (tDCS) versus active comparators for self‑repo
In a population-based Alberta cohort, women with incident stage 5 CKD lost the usual female survival advantage: younger women had substantially higher excess mortality than men and were less likely to receive transplants or dialysis, indepe
A 200‑patient cross‑sectional study found metformin use tripled the odds of vitamin B12 deficiency without affecting vitamins A, B1, B6, B9, C or E, highlighting the need for targeted B12 monitoring in long‑term metformin therapy.
Summarizes emerging expert consensus on ultra‑low‑dose quadruple antihypertensive therapy (the “quadpill”) after QUARTET and related evidence, with practical recommendations and caveats for clinical use.
A personalized clinical decision support tool increased 30‑day reinitiation of ACE inhibitors or ARBs from 13% to 18% among veterans with CKD; benefits were modest and limited by population and implementation factors.
A single‑centre randomized trial in China found that 7 days of remote ischemic conditioning (RIC) reduced average systolic BP by about 4.8 mm Hg versus sham in patients with essential hypertension (SBP ≥140 mm Hg), with good tolerability.
The GoFresh randomized trial found that 12 weeks of home‑delivered DASH‑patterned groceries plus dietitian counseling reduced systolic BP by 3.4 mm Hg versus cash stipends and lowered LDL; effects were not sustained three months after the i
The PERMET randomized, double-blind trial found that 6 months of metformin did not improve 6-minute walk distance or other functional endpoints in people with lower extremity peripheral artery disease (PAD) without diabetes.
In a prospective Beijing cohort (BLINDSCE), each additional hour of daily sedentary time was associated with a 1.18-point lower baseline intrinsic capacity and a 0.48-point greater decline over 1 year, suggesting sedentary behavior is a mod
A meta-analysis of 36 RCTs (n=2,500) found aerobic exercise significantly reduces depressive symptoms in people with chronic illness (Hedges’ g -0.73). A weekly dose of ≈405 MET‑min (≈120–135 min of moderate aerobic activity) reaches
A pooled analysis of three population cohorts shows lean MASLD carries higher risks of liver-related events and all-cause and liver-related mortality despite lower cardiovascular event risk compared with non-lean MASLD.
Nonceliac gluten/wheat sensitivity affects about 1 in 10 people worldwide, with strong links to female sex, psychological distress, and irritable bowel syndrome. This article explores its prevalence, symptoms, challenges in diagnosis, and i
In a 48‑week multicenter phase 2 trial, weekly amylin receptor agonist eloralintide produced dose‑dependent mean weight loss of 9.4%–20.9% versus 0.4% for placebo, with improved waist circumference and cardiometabolic markers; tolerability
Open language-specific specialty feeds and department pages.